Comparative Pharmacology
Head-to-head clinical analysis: AMLODIPINE BESYLATE BENAZEPRIL HYDROCHLORIDE versus GRAFAPEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMLODIPINE BESYLATE BENAZEPRIL HYDROCHLORIDE versus GRAFAPEX.
AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE vs GRAFAPEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amlodipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions into vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced peripheral vascular resistance. Benazepril is an angiotensin-converting enzyme (ACE) inhibitor that prevents the conversion of angiotensin I to angiotensin II, resulting in vasodilation, decreased aldosterone secretion, and reduced blood pressure.
GRAFAPEX is a monoclonal antibody that binds to and inhibits the activity of tumor necrosis factor-alpha (TNF-α), a pro-inflammatory cytokine involved in immune-mediated inflammatory diseases.
Oral, 1 capsule (amlodipine 2.5-10 mg / benazepril 10-40 mg) once daily. Start with amlodipine 2.5 mg / benazepril 10 mg, titrate based on response.
10-20 mg orally once daily, maximum 40 mg per day.
None Documented
None Documented
Amlodipine: terminal elimination half-life 30-50 hours (mean ~35 h), allowing once-daily dosing. Benazeprilat: effective half-life 10-11 hours; terminal half-life ~22 hours, with prolonged effects in renal impairment.
Terminal elimination half-life: 12 hours (range 10-14 hours); clinical context: dosing interval recommended every 24 hours to maintain therapeutic levels
Amlodipine: ~90% metabolized to inactive metabolites, ~10% excreted unchanged in urine; metabolites excreted renally (~60%) and fecally (~20-25%). Benazepril: hydrolyzed to benazeprilat, which undergoes renal excretion (~33% as unchanged drug and metabolites) and biliary/fecal excretion (~33%), with the remainder via other routes.
Renal: 60% as unchanged drug; biliary/fecal: 30%; minor metabolism: 10%
Category D/X
Category C
ACE Inhibitor
ACE Inhibitor